Jerusalem Pharmaceutical Co (XPAE:JPH) Beginning Cash Position: $11.57 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAE:JPH Jerusalem Pharmaceutical Co XPAE:JPH
76 GF Score
Price $3.55
GF Value $2.47
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jerusalem Pharmaceutical Co Beginning Cash Position?

Jerusalem Pharmaceutical Co XPAE:JPH -2.47% 76 Beginning Cash Position is $11.57 Mil as of Jun. 2026. GuruFocus rates XPAE:JPH with a GF Score™ of 76/100 and a GF Value™ of $2.47 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Jerusalem Pharmaceutical Co's Beginning Cash Position for the quarter that ended in Jun. 2026 was $11.57 Mil.

Jerusalem Pharmaceutical Co's quarterly Beginning Cash Position increased from Dec. 2025 ($11.34 Mil) to Mar. 2026 ($12.22 Mil) but then declined from Mar. 2026 ($12.22 Mil) to Jun. 2026 ($11.57 Mil).

Jerusalem Pharmaceutical Co's annual Beginning Cash Position declined from Dec. 2023 ($7.73 Mil) to Dec. 2024 ($6.59 Mil) but then increased from Dec. 2024 ($6.59 Mil) to Dec. 2025 ($11.74 Mil).

Jerusalem Pharmaceutical Co Beginning Cash Position Related Terms

Jerusalem Pharmaceutical Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Jerusalem Pharmaceutical Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jerusalem Pharmaceutical Co Beginning Cash Position Chart

Jerusalem Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.96 5.44 7.73 6.59 11.74

Jerusalem Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.05 14.51 11.34 12.22 11.57
XPAE:JPH
76GF Score
Jerusalem Pharmaceutical Co XPAE:JPH
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jerusalem Pharmaceutical Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $11.57 Mil mean?
Jerusalem Pharmaceutical Co (XPAE:JPH) has a Beginning Cash Position of $11.57 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Jerusalem Pharmaceutical Co and its competitors.
Is Jerusalem Pharmaceutical Co's Beginning Cash Position too high?
Jerusalem Pharmaceutical Co's current Beginning Cash Position is $11.57 Mil. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's Beginning Cash Position compare to ZTS and UTHR?
Jerusalem Pharmaceutical Co's Beginning Cash Position of $11.57 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Jerusalem Pharmaceutical Co and its competitors. Jerusalem Pharmaceutical Co's current Beginning Cash Position is $11.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.47, compared to a current price of $3.55 — trading 43.7% above its estimated fair value. The current Beginning Cash Position is $11.57 Mil. Jerusalem Pharmaceutical Co's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current Beginning Cash Position is $11.57 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?

Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued. The current stock price of $3.55 is trading 43.7% above its estimated GF Value™ of $2.47. GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for XPAE:JPH:

  • Beginning Cash Position: $11.57 Mil
  • GF Value™: $2.47 vs. price of $3.55 (43.7% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jerusalem Pharmaceutical Co Business Description

Address Nablus Street, Jerusalem Pharmaceuticals Company Buliding, Al Bireh Industrial Zone, Al Bireh, PSE, 3570
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
76GF Score

Get the complete analysis for XPAE:JPH

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price
$2.47
GF Value